Compare Impinj Inc (PI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Impinj Inc vs GeneDx Holdings Corp — how do they compare? Impinj Inc trades at $189.55 (market cap $5.60B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Impinj Inc is far larger — about 2.8× GeneDx Holdings Corp's market cap, and Impinj Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Impinj Inc for 22 Days and GeneDx Holdings Corp for 19 Days on average.
| PI | WGS | |
|---|---|---|
Market Cap | $5.60B | $2.02B |
Volume | 9,929 | 734,640 |
Sector | Technology | Health |
52-Week High | $241.91 | $167.51 |
52-Week Low | $91.34 | $34.51 |
Typical Hold Time | 22 Days | 19 Days |
Enterprise Value | $5.73B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Impinj (PI) trades at $183.37, down 4.01% today, with strong analyst support (16 Buy, 0 Sell) and a $178.83 consensus target. Recent Q2 2026 earnings beat expectations ($0.86 vs. $0.795), but the company remains unprofitable with a -7.26% net margin. Technical indicators show a bullish trend, with support at $181 and resistance at $188. The stock is positioned near its pivot point of $185 amid ongoing operational growth in RFID technology.
Outlook: PI offers growth potential in RFID markets, but profitability concerns and high valuations (P/S 14.83, EV/EBITDA 523.68) pose risks. Investors should weigh strong revenue trends against negative margins and monitor Q3 2026 results for sustained execution. Near-term price action may hinge on technical support levels and institutional sentiment.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
